凝血因子VIII:新兴血友病A疗法的生物基础
Benjamin J Samelson-Jones1,2, Bhavya S Doshi1,2, Lindsey A George1,2
1Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia PA.
Blood
|August 1, 2024
概括
了解 VIII 凝血因子 (FVIII) 生物学方面的进展推动了 A 型血友病 (HA) 治疗的创新. 新的疗法,包括双特异性抗体和基因疗法,为患有FVIII缺乏症的患者提供了改善的结果.
科学领域:
- 血液学 血液学 血液学
- 生物技术是生物技术.
- 分子生物学分子生物学
背景情况:
- 凝血因子VIII (FVIII) 对于静血至关重要,它与FIXa形成内在的Xase复合体,以激活FX.
- 血友病A (HA) 是由FVIII缺乏引起的,影响血液凝固.
- 了解FVIII生物学的近期进展刺激了治疗方面的进步.
研究的目的:
- 审查最近在血友病A治疗中的生物技术创新.
- 突出FVIII生物学在指导新治疗策略中的作用.
- 讨论开发功能增益的FVIII变体,以改善基因疗法.
主要方法:
- 审查FVIII生物学,包括分泌,辅因子活性和免疫性.
- 对最近对HA疗法的监管批准进行分析.
- 检查第二代rAAV载体的功能增益FVIII变体.
主要成果:
- 生物技术的创新已经导致FVIII模仿双特异性抗体和RAAV基因治疗HA的监管批准.
- 正在为第二代rAAV载体开发功能增益的FVIII变体,其分泌能力得到改善.
- 这些先进的疗法正在进入临床试验,显示HA治疗的前景.
结论:
- 对FVIII生物学的持续研究对于开发更有效的血友病疗法至关重要.
- 新的治疗方式正在改善A型血友病的治疗.
- 最终的目标是使血液静止正常化,并通过减少治疗负担来提高患者的福祉.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
659
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
659
Extrinsic and Intrinsic Pathways of Hemostasis
6.8K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
6.8K
Disorders of Hemostasis
781
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
781
Introduction to Hemostasis
6.9K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
6.9K
Role of Hematopoietic Growth Factors
1.3K
Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
Thrombopoietin (TPO), mainly released by the liver,...
1.3K
Clot Retraction and Fibrinolysis
5.2K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
5.2K


